ΔΙΑΛΕΞΗ E.YAKIREVICH 15/06/17 , ώρα 12

 

Tην Πέμπτη 15 Ιουνίου 2017 και ώρα 12:00 θα πραγματοποιηθεί διάλεξη στην Αίθουσα του Τομέα Φαρμακογνωσίας και Χημείας Φυσικών προϊόντων.

Ομιλητής: Evgeny Yakirevich, MD, DSc, Associate Professor of Pathology, The Warren Alpert Medical School of Brown University, Providence, RI, USA

Θέμα: Tyrosine Kinase Inhibitors in ALK-Rearranged Lung Cancer and Beyond: Resisting Resistance Χρόνος ομιλίας: 50 λεπτά

Περίληψη ομιλίας Gene rearrangements involving ALK receptor tyrosine kinase were first discovered in anaplastic lymphoma, and later found in several tumor types from different lineages, including hematolymphoid, mesenchymal, and epithelial. Among the epithelial cancers, they are most common in non–small cell lung cancer (NSCLC), comprising approximately 3% to 7% of lung adenocarcinoma. In this lecture, current companion molecular diagnostics and treatment of advanced ALK-rearranged NSCLC with the first generation ALK tyrosine kinase inhibitor (TKI) crizotinib and more potent next generation ALK inhibitors (ceritinib, alectinib, and lorlatinib) will be discussed. Further discussion will include a patient with refractory metastatic colorectal carcinoma harboring a novel STRN-ALK fusion who achieved an exceptional clinical benefit to the ALK inhibitor ceritinib, however after 9 months of treatment the disease progressed. The clinical benefit of targeting ALK using TKIs is limited by the emergence of drug resistance, and information regarding diverse mechanisms of acquired resistance to ALK TKI will be provided. Furthermore, development of novel therapeutic strategies to overcome resistance in the clinic will be discussed.

---